Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 8/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | DDO | Q99489 | 2/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196645 | 0.83 | DAO (0.71) | DAOCA12CA9DDOHRH4 | |
| SCHEMBL16767858 | 0.79 | DAO (1.00) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL31378942 | 0.79 | DAO (0.65) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL22198975 | 0.79 | DAO (0.65) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL28251365 | 0.77 | DAO (0.53) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL22185215 | 0.76 | DAO (0.61) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL29955653 | 0.76 | DAO (0.61) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL1534147 | 0.75 | DAO (0.47) | DAODDOHRH4KDM4E | |
| SCHEMBL22184925 | 0.75 | DAO (0.59) | DAOCA12CA9DDOAKR1B1 | |
| SCHEMBL27443353 | 0.75 | DAO (0.64) | DAOCA12CA9AKR1B1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113559105-A | Treatment of resistant acne | 维奥姆治疗有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-11045479-B2 | Treatments for resistant acne | VYOME THERAPEUTICS LIMITED (IN) | 2021-06-29 | — | — | US | claimed |
| US-20180318313-A1 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2018-11-08 | — | — | US | claimed |
| EP-3099301-A2 | TREATMENTS FOR RESISTANT ACNE | Vyome Biosciences Pvt Ltd (IN) | 2016-12-07 | — | — | EP | claimed |
| US-20160346294-A1 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2016-12-01 | — | — | US | claimed |
| WO-2015114666-A9 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2016-10-20 | — | — | WO | claimed |
| WO-2015114666-A2 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2015-08-06 | — | — | WO | claimed |
| CN-108815119-B | Pharmaceutical composition containing besifloxacin hydrochloride and preparation method thereof | 江苏亚邦爱普森药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220288086-A1 | TREATMENT FOR BACTERIAL INFECTION | VYOME THERAPEUTICS LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
| CN-113559105-A | Treatment of resistant acne | 维奥姆治疗有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-106163526-B | Treatment of resistant acne | 维奥姆治疗有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11045479-B2 | Treatments for resistant acne | VYOME THERAPEUTICS LIMITED (IN) | 2021-06-29 | — | — | US | disclosed |
| EP-3698793-A1 | BESIFLOXACIN FOR THE TREATMENT OF RESISTANT ACNE | Vyome Therapeutics Limited (IN) | 2020-08-26 | — | — | EP | disclosed |
| EP-3099301-A2 | TREATMENTS FOR RESISTANT ACNE | Vyome Biosciences Pvt Ltd (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346294-A1 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015114666-A9 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2016-10-20 | — | — | WO | disclosed |
| WO-2015114666-A2 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2015-08-06 | — | — | WO | disclosed |
| US-8415342-B2 | Besifloxacin ophthalmic composition for the treatment or control of infection | BAUSCH & LOMB INCORPORATED (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2010051291-A1 | BESIFLOXACIN OPHTHALMIC COMPOSITION FOR THE TREATMENT OR CONTROL OF INFECTION | BAUSCH & LOMB INCORPORATED (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105662-A1 | Besifloxacin Ophthalmic Composition for the Treatment or Control of Infection | MEDICIS PHARMACEUTICAL CORPORATION | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288086-A1 | TREATMENT FOR BACTERIAL INFECTION | ELANE, CFTR, TLR5 | DAO 2827/4885CA12 3841/4885CA9 4202/4885 |
| US-20100105662-A1 | Besifloxacin Ophthalmic Composition for the Treatment or Control of Infection | BLM, BROX, CRYAB | DAO 1981/4885CA12 3635/4885CA9 1971/4885 |
| US-20180318313-A1 | TREATMENTS FOR RESISTANT ACNE | RARB, CUTA, RARG | DAO 1708/4885CA12 4434/4885CA9 4628/4885 |
| US-20160346294-A1 | TREATMENTS FOR RESISTANT ACNE | CUTA, RARB, RARG | DAO 2004/4885CA12 4248/4885CA9 4583/4885 |
| US-11045479-B2 | Treatments for resistant acne | RARB, CUTA, RARG | DAO 1708/4885CA12 4434/4885CA9 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.